Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Amortizatization of Intangibles (2018 - 2019)

BeOne Medicines (BEIGF) has disclosed Amortizatization of Intangibles for 2 consecutive years, with -$51000.0 as the latest value for Q3 2019.

  • Quarterly Amortizatization of Intangibles rose 98.85% to -$51000.0 in Q3 2019 from the year-ago period, while the trailing twelve-month figure was -$7.3 million through Sep 2019, down 64.29% year-over-year, with the annual reading at -$8.0 million for FY2018, N/A changed from the prior year.
  • Amortizatization of Intangibles for Q3 2019 was -$51000.0 at BeOne Medicines, up from -$1.2 million in the prior quarter.
  • The five-year high for Amortizatization of Intangibles was -$51000.0 in Q3 2019, with the low at -$4.4 million in Q3 2018.